Roger Lo on the Evolution of Melanoma During Therapy

Article

Roger Lo, MD, PhD, UCLA Jonsson Comprehensive Cancer Center, discusses the evolution of metastatic melanoma during therapy.

Roger Lo, MD, PhD, UCLA Jonsson Comprehensive Cancer Center, discusses the evolution of metastatic melanoma during therapy.

Because of mutations in the BRAF gene, patients become resistant to anti-BRAF treatment after a period of time and the tumors start to grow again.

Lo and investigators used genomic and epigenomic profiling to detect changes in the genes’ activities inside the tumor and evaluate the function of the immune cells.

They found that the altered tumor cell behavior originates from the gene activity regulatory mechanism called CpG methylation.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
Image of a woman with blonde hair wearing a white and black blazer
2 experts are featured in this series.
2 experts are featured in this series.